Enanta Pharmaceuticals (ENTA) Peer Comparison

$11.34

$-0.28 (-2.41%)

As on 23-Oct-2026 13:32EDT

Market cap

$323 Mln

Revenue (TTM)

$65 Mln

P/E Ratio

--

P/B Ratio

3.4

Div. Yield

0 %

Edit

	Enanta Pharmaceuticals (ENTA)	Ascendis Pharma A/S - ADR	Crinetics Pharmaceuticals (CRNX)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Immunitybio Inc (IBRX)	Krystal Biotech (KRYS)	Kymera Therapeutics (KYMR)	Madrigal Pharmaceuticals (MDGL)	Medpace Holdings (MEDP)
Market cap ($ Mln)	323	14,822	9,013	15,419	13,829	9,729	9,370	8,619	10,391	17,263
Revenue ($ Mln)	65	1,054	42	2,436	1,664	166	440	105	1,284	2,782
Net Profit ($ Mln)	-63.23	755.85	-501.61	860.62	413.60	-992.36	241.47	-299.65	-325.10	491.50
Net Margin (%)	-96.89	71.69	-1,189.88	35.33	24.86	-598.56	54.82	-285.41	-25.32	17.67
RoE (%)	-55.55	--	-45.93	42.98	430.03	--	18.73	-19.40	-57.72	110.09
Price to Earnings	--	17.26	--	19.63	35.63	--	39.67	--	--	36.32
Price-To-Book	3.44	8.91	7.56	7.82	88.91	--	7.44	6.36	22.63	39.70

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Operating Revenue	65.26	2,782.29	2,435.92	1,054.37	1,663.74
Cost of Revenue	3.70	1,982.07	85.67	103.47	292.42
Gross Profit	60.74	760.62	2,236.43	588.53	1,167.84
Operating Expenses	122.78	216.81	1,378.74	841.45	440.53
Operating Profit (EBIT)	-58.73	583.40	971.51	109.45	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-63.13	598.92	1,035.47	101.11	583.34
Provision for Tax	0.10	107.42	174.84	-654.74	169.74
Profit after Tax (Net Income)	-63.23	491.50	860.62	755.85	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Shareholder's Funds	101.07	433.86	1,843.76	1,435.90	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	141.64	187.89	288.55	384.48	2,089.43
Current Liabilities	54.17	1,435.43	361.93	464.70	344.44
Total Liabilities	280.73	1,975.47	2,844.42	1,302.02	2,525.32

Assets ($ Mln)

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Non-Current Assets	93.25	1,006.90	1,243.41	895.24	1,644.38
Current Assets	203.62	1,050.29	1,250.82	1,389.84	933.02
Total Assets	280.73	1,975.47	2,844.42	1,302.02	2,525.32
Total Debt*	55.66	144.11	165.93	449.89	2,146.65
Net Current Assets	149.45	-385.14	888.90	925.52	588.59

Cashflow ($ Mln)

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-19.27	713.22	884.27	51.77	651.56
Cash Flow from Investing Activities	40.35	-31.14	350.44	-8.15	-545.81
Cash from Financing Activities	-26.62	-860.39	-969.59	34.89	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
ROCE (%)	-26.39	57.43	32.82	-30.01	15.61
ROE (%)	-55.55	110.09	42.98	163.18	430.03
ROA (%)	-18.15	15.64	29.32	31.68	16.19
EBIT Margin (%)	-76.95	21.13	41.82	5.73	36.28
Net Margin (%)	-96.89	17.67	35.33	71.69	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Revenue Growth (%)	0.70	24.67	9.23	114.85	41.15
EBIT Growth (%)	41.74	18.70	29.37	136.39	-14.99
Net Profit Growth (%)	31.28	17.50	42.89	378.76	-25.78
EPS Growth (%)	44.27	26.84	50.42	353.27	-23.48
Book Value Growth (%)	-6.56	164.02	-0.70	816.12	-55.81

Valuation Ratios

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Price / Earnings	-3.13	36.06	15.79	-59.76	24.99
Price / Book Value	3.95	35.44	5.72	-80.42	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.79	27.88	12.44	-121.54	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.00	0.27	13.50
Short term debt to equity ratio	0.04	0.06	0.00	0.05	1.46
Current Ratio	3.76	0.73	3.46	2.99	2.71
Quick Ratio	3.76	0.73	3.38	2.32	2.31
Interest Coverage	-3.89	--	--	1.62	29.73

Operating Efficiency Ratios

	Enanta Pharmaceuticals (ENTA)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debtors to sales (%)	10.01	15.88	13.74	21.25	27.40
Asset Turnover	0.19	0.89	0.83	0.44	0.65
Receivable days	127.28	50.42	43.48	85.52	98.04
Inventory Days	--	--	96.17	1,056.70	254.12
Payable days	396.23	6.26	147.97	331.01	24.86
Cash Conversion Cycle	--	--	-8.32	811.21	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly